carlisle & Associates
generic drug updates News contact carlisle medical
generic drug updates
Generic of Dilantin® Chewable Tablets Launches
Released: 01/07/2013
By: Mike Partridge, RPh

On December 27, 2012, Mylan received final FDA approval for the generic equivalent of Pfizer’s Dilantin® Chewable Tablets. Dilantin Infatabs® had estimated total U.S. annual sales of approximately $16.5 million for the twelve months ending September 2012, according to IMS.

Dilantin Infatabs® are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. However, like many other seizure medications, it may also be effective for nerve pain treatment (though it is not approved for this use).

Company News Releases
Generic Drug Updates
Newsletter Subscription
Newsletter Login
© Copyright 2019 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer